Statin use and gene variants with lifelong lowering of LDL-C levels (whether it is HMG CoA reductase, PCSK9, or NPCIL1) have been associated with an increased risk of T2DM (25–27); however, in this analysis, no clinically relevant effect of alirocumab on glycemic measures was observed, with no significant differences in change from baseline to W24 in HbA1c and FPG levels. This evidence concerns the gene PCSK9 and type 2 diabetes mellitus.